SCHEMBL14980285

SCHEMBL14980285

CN(C)CCNC1CCN(C)CC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MITF O75030 1/20 0.40
DPP7 Q9UHL4 1/20 0.39
VCP P55072 3/20 0.39
OPRL1 P41146 4/20 0.35
EHMT2 Q96KQ7 2/20 0.35
KDM1A O60341 1/20 0.35
RCOR1 Q9UKL0 1/20 0.35
PKM P14618 1/20 0.35
EHMT1 Q9H9B1 1/20 0.34
PRMT3 O60678 1/20 0.34
CARM1 Q86X55 1/20 0.34
PRMT6 Q96LA8 1/20 0.34
PRMT1 Q99873 1/20 0.34
PRMT8 Q9NR22 1/20 0.34
NCF1 P14598 1/20 0.34
POLB P06746 2/20 0.34
ALDH1A1 P00352 1/20 0.34
RECQL P46063 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4651637 0.98 MEN1 (0.39) MEN1KMT2AMITFDPP7VCP
SCHEMBL24204325 0.88 TDP1 (0.43) MEN1KMT2AMITFDPP7VCP
SCHEMBL24204664 0.85 MEN1 (0.47) MEN1KMT2AMITFDPP7OPRL1
SCHEMBL6013549 0.83
SCHEMBL24171724 0.82 VCP (0.38) VCPPKMPRMT3CARM1PRMT6
Hydrochloric Acid SCHEMBL31097152 0.81 ALDH1A1 (0.43) KMT2AVCPOPRL1PKMPRMT3
SCHEMBL26005369 0.80 MEN1 (0.36) MEN1KMT2AMITFDPP7OPRL1
SCHEMBL16219402 0.79 VCP (0.39) VCPPKMPRMT3CARM1PRMT6
SCHEMBL20466373 0.79 WHR1 (0.42) VCPEHMT2KDM1AEHMT1ALDH1A1
SCHEMBL14107151 0.79 PKM (0.52) PKMPRMT3CARM1PRMT6PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9790499-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2017-10-17 US disclosed
US-9278987-B2 Functionally-modified oligonucleotides and subunits thereof SAREPTA THERAPEUTICS, INC. (US) 2016-03-08 US disclosed
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2014-11-06 US disclosed
WO-2013074834-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF SAREPTA THERAPEUTICS, INC. (US) 2013-05-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140330006-A1 FUNCTIONALLY-MODIFIED OLIGONUCLEOTIDES AND SUBUNITS THEREOF RTCB, NSUN3, NSUN2 MEN1 4108/4885KMT2A 2877/4885MITF 1915/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.